At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...
Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...
AbbVie’s stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company’s Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback